NCT00357500 · REGISTRY CONDITION SEARCH

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2014-10-01

RATIONALE: Drugs used in chemotherapy, such as etoposide and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Thalidomide, celecoxib, and fenofibrate may stop the growth of cancer cells by blocking blood flow to the cancer. Celecoxib also may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with thalidomide, celecoxib, and fenofibrate may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving etoposide and cyclophosphamide together with thalidomide, celecoxib, and fenofibrate works in treating young patients with relapsed or progressive cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome

Therapy Completion Rate

→

outcome

27-Week Progression-Free Survival

→

outcome

27-Week Overall Survival

→

outcome

Best Response

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: DISEASE CHARACTERISTICS: * Histologically confirmed cancer (at diagnosis or relapse), including any of the following: * Leukemia and/or lymphoma (closed to accrual) * Bone tumor (e.g., Ewing's sarcoma or osteosarcoma) (closed to accrual) * Neuroblastoma (closed to accrual) * High-grade glial tumor * Low-grade glial tumor * Ependymoma * Medulloblastoma and/or primitive neuroectodermal tumor (PNET) * Miscellaneous tumor (closed to accrual) * Brain stem glioma, defined as intrinsic tumors of the pons causing diffuse enlargement * Brain stem glioma that progressed after radiotherapy does not require histological confirmation * Duration of symptoms at the time of diagnosis must be \< 3 months * Symptoms should consist of cranial nerve deficits, ataxia, and/or long tract signs * Relapsed or progressive poor prognosis disease for which no available curative therapy exists PATIENT CHARACTERISTICS: * Karnofsky performance status 50-100% OR Lansky play scale 50-100% (for infants) * Life expectancy \> 2 months * Platelet count \> 75,000/mm\^3 (transfusion independent) * Absolute neutrophil count \> 1,000/mm\^3 (in patients without bone marrow disease) * Hemoglobin ≥ 9.0 g/dL * Creatinine \< 1.5 mg/dL OR creatinine clearance or glomerular filtration rate ≥ 70 mL/min * Bilirubin ≤ 1.5 mg/dL * SGPT ≤ 3 times normal * SGOT ≤ 3 times normal (4 times normal for patients on ranitidine hydrochloride) * Alkaline phosphatase ≤ 3 times normal * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective double-method contraception during and for 2 months after completion of study treatment * Must be willing to participate in the Celgene STEPS® program * Recent thromboembolic disease (e.g., deep vein thrombosis or pulmonary embolism) allowed if patient is clinically stable and the thromboembolic event occurred \> 3 weeks prior to study entry * No active infection * No active uncontrolled cardiac, hepatic, renal, or psychiatric disease ≥ grade 3 * No known allergies to sulfonamides * No concurrent illness that would obscure toxicity or dangerously alter drug metabolism * No other serious medical illness PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Recovered from prior therapy * Prior chemotherapy and/or radiotherapy allowed * Prior celecoxib allowed * Prior standard-dose IV etoposide and cyclophosphamide administered in 3-week courses allowed * No prior oral therapy with etoposide, thalidomide, cyclophosphamide, or fenofibrate for \> 2 months in duration * No other concurrent investigational agents * No other concurrent nonsteroidal anti-inflammatory drugs * Concurrent steroids and/or antiseizure medications allowed
healthy Volunteers: false
maximum Age: 21 Years
sex: ALL
std Ages: CHILD
ADULT

Treatment arms and interventions

arm Groups

description
Thalidomide: Start at 3 mg/kg (rounded to nearest 50 mg), increasing dose weekly by 50 mg as tolerated to 24 mg/kg (max 1,000 mg); Celecoxib: \< 20 kg at 100 mg; 20-50 kg at 200 mg; \> 50 kg at 400 mg; Fenofibrate: 90 mg/m2 (max 200 mg); Etoposide: 50 mg/m2; Cyclophosphamide: 2.5 mg/kg (max 100 mg); Patients receive oral etoposide once daily on days 1-21 and 43-63 (weeks 1-3 and 7-9) and oral cyclophosphamide once daily on days 22-42 (weeks 4-6). Patients also receive oral thalidomide once daily, oral celecoxib twice daily, and oral fenofibrate once daily in weeks 1-9. Treatment repeats approximately every 9 weeks for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients receive alternating etoposide and cyclophosphamide pulses (i.e., etoposide-cyclophosphamide-etoposide during courses 1 and 3 and cyclophosphamide-etoposide-cyclophosphamide during course 2).
intervention Names
Drug: celecoxib
Drug: cyclophosphamide
Drug: etoposide
Drug: fenofibrate
Drug: thalidomide
label
5-drug metronomic antiangiogenic regimen
type
EXPERIMENTAL

interventions

arm Group Labels
5-drug metronomic antiangiogenic regimen
name
celecoxib
type
DRUG
arm Group Labels
5-drug metronomic antiangiogenic regimen
name
cyclophosphamide
type
DRUG
arm Group Labels
5-drug metronomic antiangiogenic regimen
name
etoposide
type
DRUG
arm Group Labels
5-drug metronomic antiangiogenic regimen
name
fenofibrate
type
DRUG
arm Group Labels
5-drug metronomic antiangiogenic regimen
name
thalidomide
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 101
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Proportion of patients alive at 27 weeks without progressive disease (PD) and having tolerated therapy. As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Progressive disease was defined as \>/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease. For patients with leukemia PD was defined as \>/=25% or \>/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression.
measure
Therapy Completion Rate
time Frame
27 weeks

secondary Outcomes

description
27-week progression-free survival is the probability of patients remaining alive and progression-free at 27-weeks from study entry estimated using Kaplan-Meier methods. As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Progressive disease was defined as \>/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease. For patients with leukemia PD was defined as \>/=25% or \>/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression.
measure
27-Week Progression-Free Survival
time Frame
Assessed every 9 weeks on treatment and annually until death or initiation of new therapy, up to 27 weeks.
description
27-week overall survival is the probability of patients remaining alive at 27-weeks from study entry estimated using with Kaplan-Meier methods.
measure
27-Week Overall Survival
time Frame
Assessed every 9 weeks on treatment and annually until death or initiation of new therapy, up to 27 weeks.
description
As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Best response was regarded as best response at any single assessment. Response was defined as follows: complete resolution of all demonstrable tumor, complete response (CR); \>/=50% decrease in the product of the 2 maximum perpendicular diameters relative to the baseline evaluation, partial response (PR); \<50% decrease and \<25% increase in product of diameters, stable disease (SD); and \>/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease (PD). For patients with leukemia PD was defined as \>/=25% or \>/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression.
measure
Best Response
time Frame
Assessed at study entry, every 9 weeks on treatment and at treatment discontinuation, up to 27 weeks.

Full study description

brief Summary: RATIONALE: Drugs used in chemotherapy, such as etoposide and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Thalidomide, celecoxib, and fenofibrate may stop the growth of cancer cells by blocking blood flow to the cancer. Celecoxib also may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with thalidomide, celecoxib, and fenofibrate may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving etoposide and cyclophosphamide together with thalidomide, celecoxib, and fenofibrate works in treating young patients with relapsed or progressive cancer.
detailed Description: OBJECTIVES: Primary * Evaluate the activity of etoposide, cyclophosphamide, thalidomide, celecoxib, and fenofibrate, in terms of prolonging the time to disease progression, in young patients with relapsed or progressive cancer. Secondary * Determine, preliminarily, the biologic activity of this regimen, in terms of tumor response and overall survival, in these patients. * Determine the toxicity of this regimen in these patients. * Evaluate different radiographic techniques as markers of tumor response in these patients. * Evaluate the predictive ability of in vitro correlative studies as markers of tumor response. STATISTICAL DESIGN: Patients were classified into one of 8 strata according to diagnosis: leukemia/lymphoma, bone tumors, neuroblastoma, high grade glial tumors, low grade glial tumors, ependymoma, medulloblastoma/PNET, and miscellaneous. A two-stage design for each disease stratum was planned. The accrual goal at the end of the two-stage design was 20 subjects for each stratum. A stopping rule was applied after the accrual of the first 10 eligible subjects enrolled in each disease stratum. If 1 or more patients in the first 10 evaluable patients were alive and progression-free at 27 weeks and have tolerated therapy then accrual to stage two would proceed. Among 20 patients within a stratum, if 3 or more patients met primary endpoint then regimen would be considered successful. The probability of concluding the treatment is feasible is 0.95 if true success rate is 30% and 0.07 if true succes rate is 5%. Overall accrual target was 80-160 patients. Please see published manuscript (Robison et al Pediatr Blood Cancer 2014) for results within disease strata.

Source references

references

citation
Robison NJ, Campigotto F, Chi SN, Manley PE, Turner CD, Zimmerman MA, Chordas CA, Werger AM, Allen JC, Goldman S, Rubin JB, Isakoff MS, Pan WJ, Khatib ZA, Comito MA, Bendel AE, Pietrantonio JB, Kondrat L, Hubbs SM, Neuberg DS, Kieran MW. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer. 2014 Apr;61(4):636-42. doi: 10.1002/pbc.24794. Epub 2013 Oct 4.
pmid
24123865
type
BACKGROUND

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-83169a51e61e8cba3f9e
requested nct id
NCT00357500
primary nct id
NCT00357500
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Childhood+Oral+Cavity+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
49fb44f3c2313b6ce78cc9b6cc872fbd4126b1f54e4d7d8bb55d0d2fc959cf06
payload sha256
0c2dc4811288dc9b4c7353b46c058c0c13c50577eb3001ffe0f741633469ddeb
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-83169a51e61e8cba3f9e
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00357500
occurrences
context exact
NCT00357500
end
11
exact text
NCT00357500
start
0
offset unit
unicode_code_points
query cond
Childhood Oral Cavity Cancer
query disease state id
ds-oral-cavity-cancer-pediatric
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-oral-cavity-cancer-000.json
source file sha256
49fb44f3c2313b6ce78cc9b6cc872fbd4126b1f54e4d7d8bb55d0d2fc959cf06
source json pointer
/studies/0/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
c5dc07a7dae2d6c119730ebb5542ecc4e674322f6d4d3d784a3f72b868870f93
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Childhood+Oral+Cavity+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice